Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

India has taken a significant step forward in the field of immunology with the launch of its first dedicated complement testing laboratory, designed to improve the diagnosis of complex autoimmune and inflammatory diseases.

The US Food and Drug Administration on Tuesday released a proposal to reclassify companion diagnostic assays from Class III medical devices to Class II devices.

The College of American Pathologists (CAP) on Monday released guidelines for accurate diagnosis of amyloidosis, emphasizing the importance of identifying subtypes of the rare disease caused by hereditary mutations that can be targeted for treatment.

Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced a collaboration to develop drug-response biomarkers for glucagon-like peptide-1 receptor agonist (GLP-1) therapies. The resulting insights will potentially underpin a payor-facing test to inform reimbursement policy for these widely prescribed drugs based on a patient's potential to tolerate and respond to a drug in specific indications.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.86 billion for the fourth quarter ended October 31, 2025, exceeding revenue guidance and representing growth of 9.4% reported and up 7.2% core(1) compared with the fourth quarter of 2024.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

GE HealthCare (Nasdaq: GEHC) announced it has entered into an agreement to acquire Intelerad, a leading medical imaging software provider for the healthcare industry, for a purchase price of $2.3 billion paid in cash. This acquisition demonstrates GE HealthCare’s continued commitment to cloud-enabled and AI-powered solutions across care settings and furthers the company’s aim to triple its offerings of cloud-enabled products by 2028.

Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1tn market valuation, a sharp turnaround from this summer when its stock was hit by disappointing results for a new obesity pill.

Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS® (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim. The test allows clinicians and pathologists to assess if non-small cell lung cancer (NSCLC) tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations.